Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ok Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$8,456,068

1,196 payments

Through program year 2025, Ok Clinical Research LLC is reported as receiving $8,456,068 in research payments, across 1,196 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,884,621 172
2024 Research $689,379 225
2023 Research $1,245,204 219
2022 Research $878,163 135
2021 Research $1,398,902 192
2020 Research $1,188,816 140
2019 Research $1,170,982 113

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $3,868,475 453 payments
  2. Genentech, Inc. $1,892,861 266 payments
  3. Allergan Inc. $891,599 90 payments
  4. Biohaven Pharmaceuticals, Inc. $369,614 41 payments
  5. Genzyme Corporation $320,566 27 payments
  6. Pfizer Inc. $255,216 18 payments
  7. Cipla USA Inc. $243,048 137 payments
  8. Chiesi USA, Inc. $222,175 90 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $205,830 19 payments
  10. Teva Pharmaceuticals USA, Inc. $112,328 26 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ph2a of Anti Tryptase Beta in Patients $664,308 85 payments
  2. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $621,383 85 payments
  3. Ph III OLE of Astegolimab in COPD $615,180 71 payments
  4. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $613,374 110 payments
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $565,752 28 payments
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma $472,320 55 payments
  7. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $403,731 38 payments
  8. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $394,243 93 payments
  9. An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 $376,729 23 payments
  10. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study $283,754 27 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record